title: Efficacy and Safety of Combination Therapy Consisting of Angiotensin II Type 1 Receptor Blocker, Calcium Channel Blocker and Hydrochlorothiazide in Patients With Hypertension.
abstract: BACKGROUND
  Many patients continue to have high blood pressure (BP) even after treatment with high-dose (H)-angiotensin II type 1 receptor blocker (ARB)/calcium channel blocker (CCB) or middle-dose (M)-ARB/CCB/hydrochlorothiazide (HCTZ).
  
  
  METHODS
  Thirty-two hypertensive patients who had the use of H-ARB/CCB or M-ARB/CCB/HCTZ were enrolled in this study. We applied a changeover with a switch to H-ARB (telmisartan 80 mg/day)/CCB (amlodipine 5 mg/day or nifedipine CR 40 mg/day)/HCTZ (12.5 mg/day).
  
  
  RESULTS
  Systolic BP (SBP) and diastolic BP (DBP) were significantly decreased in all patients and in the H-ARB/CCB and M-ARB/CCB/HCTZ groups after 3 months. Percentage (%) of patients who reached the target BP after 3 months (72%) in all patients was significantly higher than that at 0 months (19%). There were no serious adverse effects in any of the patients.
  
  
  CONCLUSIONS
  Combination therapy with H-ARB/CCB/HCTZ was associated with a significant reduction of BP.
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan; Inoue Hospital, Fukuoka, Japan; Shirotani Hospital, Fukuoka, Japan.
authors.forename: Yuhei
authors.initials: Y
authors.lastname: Shiga
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
authors.forename: Shin-Ichiro
authors.initials: SI
authors.lastname: Miura
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan; Fujisawa Clinic, Fukuoka, Japan.
authors.forename: Kota
authors.initials: K
authors.lastname: Motozato
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan; Inoue Hospital, Fukuoka, Japan.
authors.forename: Yuka
authors.initials: Y
authors.lastname: Yoshimine
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Norimatsu
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
authors.forename: Tadaaki
authors.initials: T
authors.lastname: Arimura
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan; Matsunaga Hospital, Fukuoka, Japan.
authors.forename: Rie
authors.initials: R
authors.lastname: Koyoshi
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
authors.forename: Joji
authors.initials: J
authors.lastname: Morii
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Kuwano
authors.affiliation: Inoue Hospital, Fukuoka, Japan.
authors.forename: Ken
authors.initials: K
authors.lastname: Inoue
authors.affiliation: Shirotani Hospital, Fukuoka, Japan.
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Shirotani
authors.affiliation: Fujisawa Clinic, Fukuoka, Japan.
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Fujisawa
authors.affiliation: Matsunaga Hospital, Fukuoka, Japan.
authors.forename: Eiyu
authors.initials: E
authors.lastname: Matsunaga
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
authors.forename: Keijiro
authors.initials: K
authors.lastname: Saku
keywords: Angiotensin II type 1 receptor blocker; Blood pressure; Calcium channel blocker; Hydrochlorothiazide